Apitegromab - Scholar Rock
Alternative Names: SRK-015Latest Information Update: 26 Sep 2025
At a glance
- Originator Scholar Rock
- Class Monoclonal antibodies; Obesity therapies
- Mechanism of Action Myostatin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Spinal muscular atrophy
- Phase II Obesity
- No development reported Spinal cord injuries
Most Recent Events
- 23 Sep 2025 Scholar Rock plans to initiate launch Apitegromab for Spinal muscular atrophy in Europe in the second half of 2026.
- 23 Sep 2025 Scholar Rock receives complete response letter from the FDA for apitegromab in Spinal Muscular Atrophy
- 23 Sep 2025 Scholar Rock expects a decision on marketing authorisation application (MAA) by European Medicines Agency near mid-2026.